Intelligence Feed event · Policy · 2026-09-29

    AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer

    Question

    AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer

    Direct answer

    AstraZeneca and partner HUTCHMED formally submitted an NDA to the US FDA for the savolitinib plus osimertinib combination regimen. The therapy addresses patients with MET-driven non-small cell lung cancer who developed resistance to initial targeted treatments. An approval would extend Tagrisso's product lifecycle and establish savolitinib's first commercial entry into the US oncology market, triggering commercial milestone schedules.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-29
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer”, revision 1, evidence through 2026-09-29. https://marketontology.com/market-events/2026-09-29/astrazeneca-files-us-fda-nda-for-savolitinib-combo-in-met-driven-lung-cancer-6144bc

    POLICY
    AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
    AstraZeneca and partner HUTCHMED formally submitted an NDA to the US FDA for the savolitinib plus osimertinib combination regimen. The therapy addresses patients with MET-driven non-small cell lung cancer who developed resistance to initial targeted treatments. An approval would extend Tagrisso's product lifecycle and establish savolitinib's first commercial entry into the US oncology market, triggering commercial milestone schedules.
    HCMAZN
    Impact
    74
    SEP 29
    SIG
    90%
    HCMAZN
    AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
    AstraZeneca and partner HUTCHMED formally submitted an NDA to the US FDA for the savolitinib plus osimertinib combination regimen. The therapy addresses patients with MET-driven non-small cell lung cancer who developed resistance to initial targeted treatments. An approval would extend Tagrisso's product lifecycle and establish savolitinib's first commercial entry into the US oncology market, triggering commercial milestone schedules.
    → Regulatory submission initiates the FDA review clock, creating prospective milestone payments and royalty expansion for HUTCHMED and expanding AstraZeneca's oncology revenue base.
    Impact
    AstraZeneca and partner HUTCHMED formally submitted an NDA to the US FDA for the savolitinib plus osimertinib combination regimen. The therapy addresses patients with MET-driven non-small cell lung cancer who developed resistance to initial targeted treatments. An approval would extend Tagrisso's product lifecycle and establish savolitinib's first commercial entry into the US oncology market, triggering commercial milestone schedules.
    Affected
    HCMAZN
    Transmission
    Regulatory submission initiates the FDA review clock, creating prospective milestone payments and royalty expansion for HUTCHMED and expanding AstraZeneca's oncology revenue base.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMmilestone cash flows and US commercial royalty visibility on FDA regulatory advancementUp1-3mAstraZeneca submitted US NDA for savolitinib (ORPATHYS) partnered with HUTCHMED
    AZNline extension and resistance-barrier moat expansion for Tagrisso oncology franchiseUp1-3mAstraZeneca submitted NDA for Tagrisso plus savolitinib combo in MET-driven NSCLC

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed14.15 2026-09-29+3.39%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month